Mesoblast Stock Price, News & Analysis

Mesoblast (Nasdaq: MESO) reported results for the quarter ended September 30, 2025. Cell therapy revenue totaled US$20.6M, up from US$12.9M the prior quarter. Ryoncil gross sales rose 66% to US$21.9M and net sales increased 69% to US$19.1M after a 12.7% gross-to-net adjustment.

The company held US$145M cash at quarter end and reported US$14.9M net operating cash spend. Mesoblast secured convertible note subscription agreements for up to US$50M (availability subject to shareholder approval). A permanent HCPCS J-code (J3402) for Ryoncil became active on Oct 1, 2025, federal Medicaid coverage is mandatory from July 1, 2025, and 40 transplant centers have been onboarded.

Mesoblast (Nasdaq: MESO) reported gross Ryoncil sales of US$21.9 million for the quarter ended September 30, 2025, a 66% increase versus the prior quarter ended June 30, 2025 with a similar gross-to-net adjustment.

Ryoncil (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell product and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD). Management cited payer reimbursement progress and noted adoption is expected to accelerate following a permanent CMS J-Code effective October 1, 2025.

Mesoblast (Nasdaq:MESO) announced that Medicare & Medicaid Services activated a permanent HCPCS J‑Code J3402 for Ryoncil (remestemcel‑L‑rknd) effective October 1, 2025. The J‑Code creates a standardized billing and reimbursement pathway for Ryoncil, intended to facilitate broader patient access and simplify payment for providers treating steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD) in children. The release notes Ryoncil is the first mesenchymal stromal cell product approved by the FDA and the only therapy approved for children under age 12 with SR‑aGvHD. Providers may submit claims using J3402 for dates of service on or after October 1, 2025, and are directed to ryoncil.com for coding guidance.

Mesoblast (NASDAQ:MESO) has confirmed that its cell therapy products, including FDA-approved Ryoncil®, are manufactured in the United States from U.S. donors and designated as U.S. origin products. This designation means they are exempt from tariffs on imported branded or patented pharmaceutical products.

Ryoncil® stands as the only FDA-approved allogeneic mesenchymal stromal cell therapy for any indication, specifically approved for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months and older. The company maintains U.S.-based manufacturing for all its products, including treatments for chronic heart failure, chronic back pain, and other inflammatory conditions.

Mesoblast (NASDAQ:MESO) presented at the Morgan Stanley and Cantor Fitzgerald Annual Global Healthcare Conferences, highlighting the successful commercial launch of Ryoncil®, their FDA-approved mesenchymal stromal cell (MSC) product.

CEO Silviu Itescu discussed the strong first quarter launch and product sales for treating children with steroid-refractory acute graft versus host disease (SR-aGvHD). The company plans to expand Ryoncil®'s indications to include adult SR-aGvHD and inflammatory bowel disease (IBD), while advancing Phase 3 milestones for their second-generation product Rexlemestrocel-L.

Mesoblast (NASDAQ:MESO) has secured an option to issue up to US$50 million in convertible notes through agreements with SurgCenter principals and existing shareholders. The 5-year convertible notes, available in US$10 million tranches, feature a 5% annual coupon and can be converted to shares at US$16.25 per ADR, representing a 126% premium to Nasdaq's closing price.

The funding, subject to shareholder approval at the upcoming AGM, will be used to repay secured lenders and support working capital needs. As part of the agreement, investors will receive a US$100,000 commitment fee and warrants for up to 5 million ordinary shares, with 2 million granted upon agreement and 3 million if Mesoblast exercises the option.

Mesoblast (NASDAQ:MESO) reported significant achievements for FY2025, highlighted by the FDA approval and successful launch of Ryoncil®, the first FDA-approved MSC therapy in the US for steroid-refractory acute graft-versus-host disease in pediatric patients. The company reported product revenue of $17.2 million, up 191% year-over-year, with Ryoncil® contributing $11.3 million in net sales in its first quarter of launch.

Financial position remains strong with $162 million cash on hand. The company expanded market coverage to over 250 million US lives and onboarded 32 transplant centers. Net loss for FY2025 was $102.1 million, compared to $88.0 million in FY2024. The company is pursuing label extensions for Ryoncil® in adults with SR-aGvHD and inflammatory bowel disease, while advancing its pipeline including Revascor® for heart failure and Rexlemestrocel-L for chronic low back pain.

Mesoblast (NASDAQ:MESO), a global leader in allogeneic cellular medicines for inflammatory diseases, has announced a webcast to discuss their full-year financial results and operational highlights for the period ending June 30, 2025.

The webcast is scheduled for Thursday, August 28 at 6:30 PM EDT (Friday, August 29, 8:30 AM AEST). Investors can access the webcast through the company's provided link, and a recording will be available on Mesoblast's investor relations webpage.

Mesoblast (NASDAQ:MESO) reported strong initial results from the commercial launch of Ryoncil®, its FDA-approved mesenchymal stromal cell product for steroid-refractory acute graft-versus-host disease in children. The company achieved $13.2 million in gross revenue from Ryoncil® sales in its first quarter post-launch (March 28 - June 30, 2025).

Key operational highlights include: onboarding of 25+ transplant centers, coverage expansion to over 250 million US lives, and implementation of mandatory state CMS coverage effective July 1. The company maintains a strong cash position of $162 million and secured seven years of orphan-drug exclusivity plus biologic exclusivity through 2036.

Additionally, Mesoblast is advancing its pipeline with ongoing developments in chronic heart failure and chronic low back pain treatments.